Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1:4:15-17.
doi: 10.1016/j.jdin.2021.05.001. eCollection 2021 Sep.

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study

Pierre-Dominique Ghislain  1 , Valérie Failla  2 , Jo Lambert  3 , Rani Soenen  3 , Lynda Grine  3 , Julio Tannous  4   5 , Françoise Guiot  6 , Fabienne Willaert  4 , Hugues Fierens  7 , Mark Vandaele  8 , Hugo Boonen  9 , Julie Saerens  9 , Véronique Meuleman  10 , Annelies Stockman  11 , Arno Belpaire  11 , Sandra Swimberghe  12 , Linda Temmerman  13 , Sam Dekeyser  13 , Jean-Michel Lambert  14 , Virginie de Schaetzen  15   16 , Michel de la Brassinne  17 , Farida Benhadou  4
Affiliations

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study

Pierre-Dominique Ghislain et al. JAAD Int. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr Ghislain provides consultancy to, receives fees as a speaker and/or investigator from, or receives grants from 10.13039/100004319Pfizer, MSD, 10.13039/100006483AbbVie, Janssen, Serono, Leo, 10.13039/100004336Novartis, 10.13039/100011110UCB, 10.13039/100002429Amgen, Eli 10.13039/100004312Lilly, 10.13039/501100009754Galderma, BMS, Meda, Maruho, Flen, Menarini, Almirall, PellePharm, and Viatris. Dr Jo Lambert has been an advisor/speaker for Janssen, Leo Pharma, AbbVie, and Novartis. Dr Grine has been a speaker for AbbVie. Dr Willaert has been an advisor/speaker for Janssen, Leo Pharma, AbbVie, Celgene, and Novartis. Dr Fierens has been an advisor for Janssen, Leo Pharma, and Novartis. Dr Vandaele has been an advisor/speaker for Janssen, Leo Pharma, and Novartis. Dr Boonen has been an advisor/speaker for Celgene, Leo Pharma, Janssen-Cilag, Lily, Novartis, UCB, Almirall, AbbVie, Fresenius Kabi, Mylan, and Sanofi. Dr de Schaetzen has been an advisor/speaker for AbbVie, Novartis, and Leo Pharma. Dr de la Brassinne has received lecture and/or consultation fees and/or travel reimbursement from AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, and Pfizer. Drs Failla, Soenen, Tannous, Guiot, Saerens, Meuleman, Stockman, Belpaire, Swimberghe, Temmerman, Dekeyser, Jean-Michel Lambert, and Benhadou have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Psoriasis disease activity under the treatment of guselkumab. A, Absolute PASI over time. B, PASI 75, PASI 90, and PASI 100 over time. The number of patients is indicated in the graph. PASI, Psoriasis Area Severity Index.
See this image and copyright information in PMC

References

    1. Benhadou F., Ghislain P.D., Guiot F. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–e839. - PubMed
    1. Langley R.G., Tsai T.F., Flavin S. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. - PubMed
    1. Blauvelt A., Papp K.A., Griffiths C.E. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. - PubMed
    1. Megna M., Fabbrocini G., Cinelli E., Camela E., Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020:1–5. - PubMed
    1. Maliyar K., O'Toole A., Gooderham M.J. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588–595. - PubMed

LinkOut - more resources